Optometrists in Jefferson, IA Accepting Medicare
6 Optometrists found. Showing 1 - 6
 Central Iowa Family Eyecare Pllc Optometrist Medicare: Medicare Enrolled Practice Location: 207 N Chestnut St, Jefferson, IA 50129 Phone: 515-386-3513 |
Jefferson Eye Care, P.c. Optometrist Medicare: Medicare Enrolled Practice Location: 117 E Lincolnway St, Jefferson, IA 50129 Phone: 515-386-8196 Fax: 515-386-2380 |
 Dr. William L Brenny, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 207 N Chestnut St, Jefferson, IA 50129 Phone: 515-386-3513 Fax: 515-465-5373 |
Eye Care Associates, P.c. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 207 N Chestnut St, Jefferson, IA 50129 Phone: 515-386-3513 Fax: 515-465-5373 |
Dr. Kyle John Stalder, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 207 N Chestnut St, Jefferson, IA 50129 Phone: 515-386-3513 |
Terry L Brown, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 117 E Lincolnway St, Jefferson, IA 50129 Phone: 515-386-8196 Fax: 515-386-8921 |
News Archive
FDA extends action date for Bristol-Myers Squibb, Pfizer's Eliquis NDA
Bristol-Myers Squibb Company and Pfizer announced today that the U.S. Food and Drug Administration (FDA) has extended the action date by three months for the New Drug Application (NDA) for Eliquis (apixaban) for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Sepracor to present clinical study data of STEDESA at the 2009 AES meeting
Sepracor Inc. today announced that clinical study data for STEDESA™ (eslicarbazepine acetate) will be presented at the 2009 annual meeting of the American Epilepsy Society (AES) in Boston. Seven posters describing new safety analyses will be presented at the Hynes Convention Center during the formal poster session on Saturday, December 5, 2009 between 1:00 pm and 8:00 pm EST.
FDA issues warning letter to Cambrex concerning its Italian API manufacturing facility
Cambrex Corporation (the "Company") announced that it has received a warning letter from the U.S. Food and Drug Administration ("FDA") relating to an inspection of the Company's generic active pharmaceutical ingredient ("API") manufacturing facility located in Milan, Italy in March 2009. The observations noted in the warning letter are primarily related to the collection and maintenance of certain laboratory data.
Study reveals growing problem of diabetic retinopathy among youth
Blindness and eye problems may seem far in the future for children and teenagers with diabetes. But a new study shows these concerns shouldn't be overlooked in those with the condition — of any age.
Ophthalmologists focus on dim-light driving situations that can endanger drivers and pedestrians
As the end of daylight saving time draws near, ophthalmologists at the Vanderbilt Eye Institute want to focus on a real issue — dim-light driving situations that can endanger drivers and pedestrians.
› Verified 4 days ago
Chiropractors
Optometrists
Physical Therapists
Occupational Therapists